Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabin IPV with routine infant vaccines in Bangladesh and Pakistan
NCT05850364Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- May 2023
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (4 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rate of polio vaccination when administered concomitantly with routine vaccines at 28 days and Adverse Reactions (Vaccine-related Adverse Events) at 7 days. Started May 2023; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT05850364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05850364.